Advertisement
CLOV vs HUM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLOV is a Buy and HUM is a StrongBuy.
CLOV's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CLOV turned positive on November 09, 2026. Looking at past instances where CLOV's MACD turned positive, the stock continued to rise in 40 of 47 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 56 cases where CLOV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CLOV as a result. In 60 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
CLOV moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLOV advanced for three days, in 225 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CLOV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLOV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLOV's P/B Ratio (6.804) is slightly higher than the industry average of (3.520). P/E Ratio (-120.500) is within average values for comparable stocks, (126.353). CLOV's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.970) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating fairly steady price growth. CLOV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Momentum Indicator for HUM turns positive, indicating new upward trend
HUM saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned positive. In 54 of the 78 cases, the stock moved higher in the following days. The odds of a move higher are at 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for HUM just turned positive on November 10, 2026. Looking at past instances where HUM's MACD turned positive, the stock continued to rise in 34 of 50 cases over the following month. The odds of a continued upward trend are 68%.
Following a +5.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUM advanced for three days, in 223 of 349 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for HUM moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 21 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
HUM broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. HUM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.711) is normal, around the industry mean (3.520). P/E Ratio (40.612) is within average values for comparable stocks, (126.353). HUM's Projected Growth (PEG Ratio) (1.304) is slightly higher than the industry average of (0.786). Dividend Yield (0.008) settles around the average of (0.009) among similar stocks. P/S Ratio (0.319) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 93 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
CLOV | HUM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 17 | 71 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 93 | |
SMR RATING 1..100 | 92 | 98 | |
PRICE GROWTH RATING 1..100 | 38 | 8 | |
P/E GROWTH RATING 1..100 | 55 | 6 | |
SEASONALITY SCORE 1..100 | 45 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CLOV's Valuation (5) in the null industry is significantly better than the same rating for HUM (82) in the Managed Health Care industry. This means that CLOV’s stock grew significantly faster than HUM’s over the last 12 months.
HUM's Profit vs Risk Rating (93) in the Managed Health Care industry is in the same range as CLOV (100) in the null industry. This means that HUM’s stock grew similarly to CLOV’s over the last 12 months.
CLOV's SMR Rating (92) in the null industry is in the same range as HUM (98) in the Managed Health Care industry. This means that CLOV’s stock grew similarly to HUM’s over the last 12 months.
HUM's Price Growth Rating (8) in the Managed Health Care industry is in the same range as CLOV (38) in the null industry. This means that HUM’s stock grew similarly to CLOV’s over the last 12 months.
HUM's P/E Growth Rating (6) in the Managed Health Care industry is somewhat better than the same rating for CLOV (55) in the null industry. This means that HUM’s stock grew somewhat faster than CLOV’s over the last 12 months.
| CLOV | HUM | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 68% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 74% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 69% |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 68% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 64% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 65% |
| Advances ODDS (%) | 2 days ago 82% | 2 days ago 64% |
| Declines ODDS (%) | 10 days ago 85% | 8 days ago 65% |
| BollingerBands ODDS (%) | 2 days ago 81% | 2 days ago 67% |
| Aroon ODDS (%) | N/A | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLOV’s FA Score shows that 1 FA rating(s) are green while HUM’s FA Score has 2 green FA rating(s).
- CLOV’s FA Score: 1 green, 4 red.
- HUM’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLOV’s TA Score shows that 6 TA indicator(s) are bullish while HUM’s TA Score has 3 bullish TA indicator(s).
- CLOV’s TA Score: 6 bullish, 1 bearish.
- HUM’s TA Score: 3 bullish, 4 bearish.
Price Growth
CLOV (@Managed Health Care) experienced а +5.97% price change this week, while HUM (@Managed Health Care) price change was +6.92% for the same time period.
The average weekly price growth across all stocks in the @Managed Health Care industry was +1.93%. For the same industry, the average monthly price growth was +4.07%, and the average quarterly price growth was +16.14%.
Reported Earning Dates
CLOV is expected to report earnings on Mar 04, 2027.
HUM is expected to report earnings on Feb 03, 2027.
Industries' Descriptions
@Managed Health Care (+1.93% weekly)Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.
Advertisement
CLOV and
Correlation & Price change
A.I.dvisor indicates that over the last year, CLOV has been loosely correlated with ALHC. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CLOV jumps, then ALHC could also see price increases.
| Ticker / NAME | Correlation To CLOV | 1D Price Change % | ||
|---|---|---|---|---|
| CLOV | 100% | +0.81% | ||
| ALHC - CLOV | 39% Loosely correlated | +0.26% | ||
| OSCR - CLOV | 35% Loosely correlated | -4.06% | ||
| PGNY - CLOV | 23% Poorly correlated | +0.19% | ||
| HUM - CLOV | 6% Poorly correlated | +1.88% | ||
| MOH - CLOV | 4% Poorly correlated | +1.41% | ||
More | ||||
HUM and
Correlation & Price change
A.I.dvisor indicates that over the last year, HUM has been closely correlated with UNH. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if HUM jumps, then UNH could also see price increases.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AVAZ | 10.46 | 0.77 | +7.96% |
| 2x Avalanche ETF (AVAZ) | |||
| GLV | 5.95 | 0.06 | +1.00% |
| Clough Global Dividend and Income Fund | |||
| RCG | 2.70 | 0.02 | +0.75% |
| RENN Fund | |||
| GNOV | 43.37 | 0.24 | +0.55% |
| FT Vest U.S. Equity Moderate Buffer ETF - November (GNOV) | |||
| PBPH | 31.64 | N/A | N/A |
| Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) | |||